CARLSBAD, Calif., April 1, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) will exhibit products across the spectrum of basic, translational and clinical cancer research during the American Association of Cancer Research (AACR) Annual Meeting 2012, taking place March 31 – April 4, in Chicago, Illinois. In addition, several of Life's customers and collaborators will present research findings.
"From basic discovery of biomarkers to validation of new drug targets and the application of genomic sequencing in clinical trials, Life Technologies provides optimized solutions specific for cancer research," said Ronnie Andrews, president of medical sciences at Life Technologies. "We share with our customers a commitment to accelerating our scientific understanding of cancer, driving to a world in which cancer becomes a manageable disease."
DNA sequencing live on the Ion Bus – The Ion Bus offers a unique opportunity to view the game-changing Ion Personal Genome Machine (PGM™) system in action. The Ion Bus will be parked outside the Chicago Hilton at the intersection of Wabash and Balboa streets. The Ion Bus will be open for tours from 6 a.m. to 10 a.m. and 5 p.m. to 9 p.m., April 1 - 3.
Triple negative breast cancer - Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab). To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010; early results will be presented by John Carpten, Ph.D., head of the Integrated Cancer Genomics Division at the Phoenix-based Translational Genomics Research Institute (TGen) on Monday, April 2 at 10:30 a.m. Life Technologies is supporting the study, which is revealing the diversity of genetic mutations in triple negative tumors.
Semiconductor sequencing of melanoma samples – George Watts, Ph.D., research assistant professor and co-director of the Genomics Shared Service at The University of Arizona Cancer Center, will present a poster demonstrating accurate, cost-effective sequencing of six commonly mutated genes in archived research samples from metastatic melanoma patients using the Life Technologies Ion Personal Genome Machine (PGM™) system. The authors state that the study represents proof of principle for "next-generation sequencing to provide robust detection of mutations in fixed tumor samples." The poster will be presented April 2, Monday morning, from 8 a.m.